Seeking Alpha

BioCryst (BCRX) is withdrawing its Investigational New Drug application for the antiviral...

BioCryst (BCRX) is withdrawing its Investigational New Drug application for the antiviral nucleoside, BCX5191, following discussions with the FDA. The agency indicated patient safety concerns over the preclinical toxicity profile of the drug at exposure levels which they believe are likely to be necessary to reduce the viral load in patients infected with the hepatitis C virus.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs